PFE — Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: US
- Exchange: NYSE
- Employees: 81,000
- Website: https://www.pfizer.com
Latest SEC filings for PFE
- 8-K — 2026-08-04
- 10-Q — 2026-08-04
- 8-K — 2026-06-18
- 8-K — 2026-06-18
- 11-K — 2026-06-16
- 11-K — 2026-06-16
- 8-K — 2026-05-05
- S-8 — 2026-05-05
- 10-Q — 2026-05-05
- 8-K — 2026-04-27
Latest PFE news
- — Pfizer sees strong response for pediatric pneumonia vaccine in mid-stage trial (seekingalpha_market)
- — Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? (The Motley Fool)
- — Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? (The Motley Fool)
- — Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? (The Motley Fool)
- — Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue (The Motley Fool)
- — Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight (GlobeNewswire Inc.)
- — Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? (Zacks Investment Research)
- — Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio? (Zacks Investment Research)
- — Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice (The Motley Fool)
- — Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing (Zacks Investment Research)
Educational tool only — not investment advice.